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Abstract: Extensive research has been done in the search for innovative treatments against colon
adenocarcinomas; however, the incidence rate of patients remains a major cause of cancer-related
deaths in Malaysia. Natural bioactive compounds such as curcumin have been substantially
studied as an alternative to anticancer drug therapies and have been surmised as a potent
agent but, nevertheless, remain deficient due to its poor cellular uptake. Therefore, efforts
now have shifted toward mimicking curcumin to synthesize novel compounds sharing similar
effects. A synthetic analog, (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one (DK1),
was recently synthesized and reported to confer improved bioavailability and selectivity toward
human breast cancer cells. This study, therefore, aims to assess the anticancer mechanism of DK1
in relation to the induction of in vitro cell death in selected human colon cancer cell lines. Using
the3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay, the cytotoxicity of DK1
towards HT29 and SW620 cell lines were investigated. Acridine orange/propidium iodide (AO/PI)
dual-staining assay and flow cytometry analyses (cell cycle analysis, Annexin/V-FITC and JC-1
assays) were incorporated to determine the mode of cell death. To further determine the mechanism
of cell death, quantitative real-time polymerase chain reaction (qRT-PCR) and proteome profiling
were conducted. Results from this study suggest that DK1 induced changes in cell morphology,
leading to a decrease in cell viability and subsequent induction of apoptosis. DK1 treatment inhibited
cell viability and proliferation 48 h post treatment with IC50 values of 7.5 ± 1.6 µM for HT29 cells
and 14.5 ± 4.3 µM for SW620 cells, causing cell cycle arrest with increased accumulation of cell
populations at the sub-G0/G1phaseof 74% and 23%, respectively. Flow cytometry analyses showed
that DK1 treatment in cancer cells induced apoptosis, as indicated by DNA fragmentation and
depolarization of the mitochondrial membrane. qRT-PCR results show significant upregulation in
the expression of caspase-9 in both HT29 and SW620 cell lines, further supporting that cell death
induction by DK1 is via an intrinsic pathway. These outcomes, therefore, demonstrate DK1 as a
potential anticancer agent for colon adenocarcinoma due to its anti-apoptotic attributes.
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1. Introduction
Cancer remains a pathological hurdle that mankind has continuously tried to overcome for many
years. Currently, colon cancer is the second leading cause of death of cancer globally, trailing lung
cancer. In most countries, the rate of colorectal incidence increases in parallel to the increment in
human development index (HDI) levels; however, it was concluded that the rates tend to alleviate
and then progressively decrease in countries with very high HDI levels [1]. The HDI level is an
index measurement of human development and how it progresses with time, which is a composite
index for three dimensions of human development: longevity, education, and standard of living [1].
An increasing number of studies have found that the factors contributing to a higher incidence of
colon cancer in men may be in part due to irregular activities of the male hormone testosterone, which
indirectly promotes early adenomagenesis [2]. Common treatments currently practiced for colon
cancer include colectomy, radiotherapy, and chemotherapy, which often leads to permanent side
effects in treated patients. Permanent side effects may also be contributed by the need to perform
colonoscopies every 1–2 years for the removal of precancerous polyps [3]. This inconvenience and the
highly invasive treatment routes, therefore, warrant efforts for alternative treatment with fewer side
effects for colon cancer patients.
Among the popular alternatives being extensively studied is the administration of natural
compounds for anticancer therapy, such as curcumin, also known as diferuloylmethane, which is a
member of the curcuminoid family. Curcumin is the main active compound found in Curcuma longa,
more commonly known as turmeric, and is used widely by Malaysian locals as a food additive
and a cosmetic ingredient. Over the years, studies have shown that curcumin possesses many
pharmacological characteristics: neuroprotective [4,5], antioxidant [6], antiinflammatory [7] and
antifungal [8], immunomodulatory [9], and antimalarial [6,10] activities. However, curcumin has
poor aqueous solubility and, therefore, much research has been conducted in developing synthetic
compounds with better solubility.
Synthetic compounds such as isoform derivatives and analogs are commonly synthesized
to overcome the weakness and limitations possessed by its parent compound. Many
studies have synthesized curcumin analogs to improve its anticancer properties [11–15].
Recently, a synthetic analog of curcumin possessing a lower molecular weight—namely,
(Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one (DK1)—was synthesized in the form of
a 100% pure crystal via the Baker–Venkataraman rearrangement method and confirmed using single
X-ray crystallography [15]. A recent study by Ali et al. found that DK1 treatment was more selective
and cytotoxic towards MCF-7 and MDA MB-213 breast cancer cell lines thantheMCF-10A normal
breast cell line and induced G2/M phase arrest in the breast cancer cells [15]. Aziz et al. reported
remarkable results where DK1 induced S phase arrest in cell cycle progression and apoptosis via the
intrinsic pathway in two bone cancer cell lines, U-2 OS and MG-63 [16]. These two studies showed
that DK1 may be a potential multi-target drug in cancer therapy. Therefore, this study aimed to assess
the potential of DK1 as a multi-target drug in cancer therapy and also to assess whether the anticancer
potential ofDK1(Figure 1) ((Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one) could be
extended to different cancer types, such as colon adenocarcinoma, by investigating the anticancer
effect and the mechanism of DK1-mediated cell death induction in human colon cancer cells (HT29
and SW620) in vitro. Our results suggest that DK1 possesses better anticancer potential than curcumin
and an ability to induce apoptosis in colorectal adenocarcinoma cell lines.
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Figure 1. The structure of (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one (DK1) as 
reported by Ali et al. (2017) [15]. 
2. Results 
2.1. DK1 Decreases Cell Viability of HT29 and SW620 
The MTT assay was used as a preliminary assessment of the anti-proliferative effects of natural 
curcumin and DK1 against two human colon cancer cell lines—HT29 and SW620. This assay was 
performed to measure the inhibitory concentrations that would kill 25%, 50%, and 75% of the total 
cell population, defined as the IC25, IC50, and IC75, respectively. Cells were treated with two-fold 
serial dilutions of the natural curcumin compound and its analog DK1 and incubated for 48 h. Table 
1 shows the inhibitory concentrations of curcumin and DK1 against HT29 and SW620 cells 48 h post 
treatment. As depicted in Table 1, the IC25 and IC50 values of DK1 in HT29 cells (2.8 µM and 7.5 µM, 
respectively) were lower than in SW620 cells (3.7 µM and 14.5 µM, respectively). However, the IC75 
values of DK1 were found to be similar between both cell lines. It was noted that within 48 h post 
incubation, the IC50 of curcumin was much higher compared to DK1 for both HT29 and SW620 cell 
lines. These inhibitory concentrations were subsequently used for the following assays conducted in 
this study. 
Table 1.The inhibitory concentrations of DK1 and natural curcumin in HT29 and SW620 colon 
carcinoma cell lines at 48 h posttreatment used as treatments in other assays. All data are expressed 
as the mean ± standard deviation (SD). 
Cell Lines 
Inhibitory Concentrations of DK1 (µM) Inhibitory Concentrations 
(IC50) of Curcumin (µM) IC25 IC50 IC75
HT29 2.8 ± 0.8 7.5 ± 1.6 28.0 ± 2.0 20.2 ± 0.6 
SW620 3.7 ± 0.9 14.5 ± 1.2 27.8 ± 1.4 >50 
DK1 = (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one. 
2.2. Treatment of DK1 Alters Morphological Appearance and Induces Apoptosis in HT29 and SW620  
The acridine orange/propidium iodide (AO/PI) dual-staining assay was carried out to observe 
morphological changes in treated cells and to semi-quantify the viable, apoptotic, and necrotic cells 
after DK1 treatments, thus elucidating the mode of cell death caused by the treatment. Viable cells 
were cells that fluoresced green with an intact cell membrane; early apoptotic cells were 
characterized by the occurrences of membrane blebbing and nuclear condensation whilst still 
fluorescing green; late apoptotic cells were characterized by a compromised membrane, nuclear 
distortion, and yellow-orange fluorescence with apoptotic bodies; and necrotic cells were cells that 
fluoresced red [15]. As depicted in Figure2, the number of viable cells decreased with dosage of DK1 
treatment, suggesting that DK1 induced apoptosis in both cell lines dosedependently. Cells were 
observed to begin displaying characteristics that indicated apoptosis in IC25 treatments of both cell 
lines, evidently more prominent in HT29 cells than in SW620 cells. As the DK1 dosage increased to 
the IC50, membrane blebbing occurred and the number of apoptotic cells increased. At the highest 
IC75 dose, the most significant increase in apoptotic populations of both HT29 and SW620 cells was 
exhibited. The cells were seen to undergo cell shrinkage. 
Figure 1. The structure of (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one (DK1) as
reported by Ali et al. (2017) [15].
2. Results
2.1. DK1 Decreases Cell Viability of HT29 and SW620
The MTT assay was used as a preliminary assessment of the anti-proliferative effects of natural
curcumin and DK1 against two human colon cancer cell lines—HT29 and SW620. This assay was
performed to measure the inhibitory concentrations that would kill 25%, 50%, and 75% of the total cell
population, defined as the IC25, IC50, and IC75, respectively. Cells were treated with two-fold serial
dilutions of the natural curcumin compound and its analog DK1 and incubated for 48 h. Table 1 shows
the inhibitory concentrations of curcumin and DK1 against HT29 and SW620 cells 48 h post treatment.
As depicted in Table 1, the IC25 and IC50 values of DK1 in HT29 cells (2.8 µM and 7.5 µM, respectively)
were lower than in SW620 cells (3.7 µM and 14.5 µM, respectively). However, the IC75 values of DK1
were found to be similar between both cell lines. It was noted that within 48 h post incubation, the IC50
of curcumin was much higher compared to DK1 for both HT29 and SW620 cell lines. These inhibitory
concentrations were subsequently used for the following assays conducted in this study.
Table 1. The inhibitory concentrations of DK1 and natural curcumin in HT29 and SW620 colon
carcinoma cell lines at 48 h posttreatment used as treatments in other assays. All data are expressed as
the mean ± standard deviation (SD).
Cell Lines
Inhibitory Concentrations of DK1 (µM) Inhibitory Concentrations
(IC50) of Curcumin (µM)IC25 IC50 IC75
HT29 2.8 ± 0.8 7.5 ± 1.6 28.0 ± 2.0 20.2 ± 0.6
SW620 3.7 ± 0.9 14.5 ± 1.2 27.8 ± 1.4 >50
DK1 = (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-ene-1-one.
2.2. Treat ent of K1 Alters orphological Appearance and Induces Apoptosis in HT29 and SW620
The acridine orange/propidiu iodide ( /PI) dual-staining assay as carried out to observe
orphological changes in treated cells and to se i-quantify the viable, apoptotic, and necrotic cells
after 1 treat ents, thus elucidating the ode of cell death caused by the treat ent. iable cells
ere cells that fluoresced green with an intact cell membrane; early apoptotic cells were characterized
by the occurrences of membrane blebbing and nuclear condensation whilst still fluorescing green; late
apoptotic cells were characterized by a compromised membrane, nuclear distortion, and yellow-orange
fluorescence with apoptotic bodies; and necrotic cells were cells that fluoresced red [15]. As depicted
in Figure 2, the number of viable cells decreased with dosage of DK1 treatment, suggesting that
DK1 induced apoptosis in both cell lines dosedependently. Cells were observed to begin displaying
characteristics that indicated apoptosis in IC25 treatments of both cell lines, evidently more prominent
in HT29 cells than in SW620 cells. As the DK1 dosage increased to the IC50, membrane blebbing
occurred and the umber of apoptotic cells increased. At the highest IC75 dose, the most significant
increase in apoptotic populations of both HT29 and SW620 cells was exhibited. The cells were seen to
undergo cell shrinkage.
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Figure 2. Representative images of morphological changes in (A) HT29 and (B) SW620 after 48 h of 
DK1 treatment (yellow arrow: viable; yellow arrowhead: early apoptotic cells; red arrowhead: late 
apoptotic cells). Cell viability quantification of (C) HT29 and (D) SW620 cells after48 h of DK1 
treatment in a population of 200 cells. EA represents early apoptosis and LA represents late 
apoptosis. All data are expressed as mean ± SD.* p > 0.05 compared to corresponding controls. 
(Magnification of objective: 20×; scale bar represents 2000 µm). 
Additionally, as shown in Figure 3, apoptotic cell populations in both cell lines showed a 
significant increase when treated with DK1. The viable HT29 cell population decreased from 96% in 
untreated control cells to 80% in IC50treatment of DK1; while in SW620 cells the viable cell 
population showed a slight decrease from 98% in untreated control cells to 88% in the IC50 treatment. 
However, a pronounced increase in the annexin-V+/PI+ quadrant, indicating late apoptosis, was 
detected from 1% of the cell population in control cells to 2% in IC25 treatment, 4% in IC50 and finally 
11% in IC75 treatments of DK1. SW620 cells also displayed a steady late apoptotic population 
increase from 2% in IC25 treatments of DK1 to approximately 10% in IC50treatments and 22% in IC75 
treatments. 
Figure 2. Representative images of morphological changes in (A) HT29 and (B) SW620 after 48 h of DK1
treatment (yellow arrow: viable; yellow arrowhead: early apoptotic cells; red arrowhead: late apoptotic
cells). Cell viability quantification of (C) HT29 and (D) SW620 cells after48 h of DK1 treatment in a
population of 200 cells. EA represents early apoptosis and LA represents late apoptosis. All data are
expressed as mean ± SD.* p > 0.05 compared to corresponding controls. (Magnification of objective:
20×; scale bar represents 2000 µm).
Additionally, as sho n in Figure 3, apoptotic cell populations in both cell lines sho ed a
significant increase hen treated ith DK1. The viable T29 cell population decreased fro 96 in
untreated control cells to 80% in IC50treatment of DK1; while in SW620 cells the viable cell population
showed a slight decrease from 98% in untreated control cells to 88% in the IC50 treatment. However,
a pronounced increase in the annexin-V+/PI+ quadrant, indicating late apoptosis, was detected from
1% of the cell population in control cells to 2% in IC25 treatment, 4% in IC50 and finally 11% in IC75
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treatments of DK1. SW620 cells also displayed a steady late apoptotic population increase from 2% in
IC25 treatments of DK1 to approximately 10% in IC50treatments and 22% in IC75 treatments.
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Figure 3. Flow cytometry annexin-V/FITC analysis.Representative histogram analyses of 
annexin-V/FITC assay after 48 h of three concentrations of DK1 treatment (IC25, IC50, and IC75)of (A) 
HT29 and (B) SW620 cells. Quantification analysis of annexin-V/FITC analysis of (C) HT29 and (D) 
SW620 cells after 48 h of DK1 treatment. EA represents early apoptosis, while LA/N represents late 
apoptosis and necrosis.All data are expressed as mean ± SD. * p < 0.05 compared with corresponding 
controls. 
2.3. Cell Cycle Arrest at G2/M Phase in HT29 and SW620 Cells 
Cancer cells have irregular cell cycle progression profiles due to the presence of growth factors 
and its inherent mutagenic nature. One favorable characteristic when formulating candidate 
compounds for cancer therapeutics is its ability to terminate the cell cycle at certain checkpoints, 
causing the treated cancer cells to be sensitized to damage. To further examine the effects of DK1 on 
the induction of apoptosis, its effects on the cell cycle was investigated. Cell cycle analysis was done 
Figure 3. Flow cytometry annexin-V/FITC analysis.Representative histogram analyses of
annexin-V/ ITC assay after 48 h of three concentration of DK1 treatment (IC25, IC50, and IC75) f
(A) HT29 and (B) SW620 cells. Quantificatio analysis of annexin-V/FIT analysis of (C) HT29
and (D) SW620 cells after 48 h of DK1 treatment. EA represents early apoptosis, while LA/N
represents late apoptosis and necrosis.All data are expressed as mean ± SD. * p < 0.05 compared
with corresponding controls.
2.3. Cell Cycle Arrest at G2/M Phase in HT29 and SW620 Cells
Cancer cells have irregular cell cycle progression profiles due to the presence of growth factors and
its inherent mutagenic nature. One favorable characteristic when formulating candidate compound
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for cancer therapeutics is its ability to terminate the cell cycle at certain checkpoints, causing the
treated cancer cells to be sensitized to damage. To further examine the effects of DK1 on the induction
of apoptosis, its effects on the cell cycle was investigated. Cell cycle analysis was done using flow
cytometry with PI to stain cellular DNA. Figure 4 shows the gradual increase in the sub-G0/G1
population of treated HT29 cells, from 4% in the untreated control group to 15%, 28%, and 74%
when exposed to three different DK1concentrations (IC25, IC50,and IC75, respectively) for 48 h. In the
treatment of SW620 cells, the sub-G0/G1 population increased to 20% and 23% when exposed to IC50
and IC75 concentrations of DK1 for 48 h. Cell cycle arrest for both cell lines occurred at the S phase
based on a significant increase in the S phase populations when treated with DK1.
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2.4. Apoptosis via Mitochondria-Dependent Pathway Induced by DK1 Treatment 
HT29 and SW620 cells were exposed to the JC-1 dye to measure their mitochondrial membrane 
potential (ΔψM). The permeabilization of the mitochondrial membrane plays an essential role in 
mitochondria-dependent apoptosis. Depolarization of the mitochondrial membrane induces the 
formation of the mitochondrial permeability transition pore, which activates the release of small 
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2.4. Apoptosis via Mitochondria-Dependent Pathway Induced by DK1 Treatment
HT29 and SW620 cells were exposed to the JC-1 dye to measure their mitochondrial membrane
potential (∆ψM). The permeabilization of the mitochondrial membrane plays an essential role in
mitochondria-dependent apoptosis. Depolarization of the mitochondrial membrane induces the
formation of the mitochondrial permeability transition pore, which activates the release of small
molecules including pro-apoptotic factors, such as cytochrome c, into the cytosol [17]. The JC-1 dye
exists in two forms: J-aggregates that fluoresce red when cells are healthy and the mitochondrial
membrane potential is high, and J-monomers (its monomeric form) that emit green fluorescence and
exist when the mitochondrial membrane potential is low. The ratio of red to green fluorescence depicts
the strength of the mitochondrial membrane potential. Thus, healthy cells will confer a higher ratio as
there would be a greater population of J-aggregates detected as compared to J-monomers. As shown in
Figure 5, the ratio of aggregates to monomers decreased as a higher dosage of DK1 was administered,
indicating that apoptosis was dosedependent.
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in the cell cycle progression at S phase, as shown in Figure 4. There was an increase in the expressions 
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observed to be upregulated in HT29, while in SW620, the expressions decreased except for the 
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Figure 5. Depolarization of mitochondrial membrane potential. Quantification analyses of the
JC-1 assay forHT29 and SW620 cells after 48 h of DK1 treatment showing the ratio of red to green
fluorescence. All data are expressed as mean ± standard deviation (SD). * p < 0.05 compared with
corresponding controls.
. . l t l t ti t i
t i at of apoptosis: t i i i t i i . I r t fi t
t i l i t - i t ll t i t ll , t t i t f
t ll f t i ti t . ff t f t t t t ll
f t as es ed by conducting qRT-PCR and human apoptosis proteome profiler. Apoptosis is mainly
regulated by th caspase cascade and a family of poptotic proteins called Bcl-2 family protein [16,18].
Caspase-3, caspase-8, and caspase-9 were hosen as th s genes are involved in the caspase cascad
that would then rigger the regulation of Bax and cytochrome c. The gene regulation of cyclin A and
Cdk 2 genes were also ass sed as they form a complex that plays an important role in the cell cycl
progression at S phas , as shown in Figure 4. There was an increase in the expressions of caspase-3,
caspase-9, cytochrome C, and Cdk 2 genes in HT 9 cell compared to SW620 cells (Figure 6). After 48 h
of DK1 (IC50) treatment, the expression l vels of human pro-apoptosis r teins such as pro-ca pase-3,
cleaved c pase-3, Bax, ytochrome C, HTRA2/Omi, and SMAC/Diablo proteins were observed to b
upr gulated in HT29, while in SW620, the expressions decreased exc pt for the increased HTRA2/Omi
prot in (Table 2).
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Pro-caspase-3 −0.98 ± 0.06 Down 
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Figure 6. qRT-PCR analyses of apoptosis and cell cycle-related genes; caspase-3 (Cas-3), caspase-8
(cas-8), caspase-9 (cas-9), Bax, cytochrome C (Cyt C), Cdk 2 (CDK2), and cyclin A (CycA) for (A) HT29
and (B) SW620 cells when treate with DK1 (IC50) for 48 h. The expressions of the target genes were
normalized to ACTB a d 18S rRNA. All data are expressed as mean ± SD. * p < 0.05 compared to
corresponding controls. The significance for t is assay was set at >2-fold changes, comparing between
the control (untreated) group and the treated group.
Table 2. Apoptosis-related protein regulation in DK1-treated HT29 and SW620 cell lines.
Cells Proteins Relative Intensity (Fold Change) Regulation
HT29
Pro-caspase-3 2.10 * ± 0.06 Up
Cleaved caspase-3 1.98 0.11 Up
Bax 2.41 * ± 0.18 Up
Cytochrome C 1.78 * ± 0.07 Up
HTRA2/ i 2.21 * ± 0.13 Up
SMAC/Diablo 1.14 0.01 Up
SW620
Pro-caspase-3 −0.98 ± 0.06 Down
Cleaved caspase-3 −0.70 ± 0.05 Down
Bax −0.75 ± 0.04 Down
Cytochrome c −0.55 ± 0.02 Down
HTRA2/Omi 1.25 * ± 0.01 Up
SMAC/Diablo −0.96 ± 0.01 Down
Note: Human apoptosis proteome profiler of HT29 and SW620 colon cancer cell lines treated with DK1 (IC50) for
48 h. All data are expressed as mean ± SD. The (−) symbol indicates downregulated protein expression. * p < 0.05
compared with corresponding controls.
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3. Discussion
The synthesis of curcumin analogs often aims to increase the potential of commercially-ready
dietary curcumin. Several studies have reported better selectivity and more effective anticancer
potentials using chemically synthesized curcumin analogs as treatments [13,14]. It was reported that
several chemically synthesized curcumin analogs had better cytotoxic effects toward a human colorectal
cancer cell line HCT-15 compared to curcumin, suggesting cell apoptosis-inducing potential [19].
Apoptosis induction is an advantageous characteristic as an anticancer agent compared to necrosis
induction because necrotic cells may cause inflammation that in turn leads to the drug conferring side
effects upon administration [18]. In this study, the potential cytotoxic effects via apoptotic pathways
using DK1 towards SW620 and HT29 colon cancer cells was assessed and the mechanism of apoptosis
induction in the cell lines was further explored. The prominent difference between these two colon
cancer cell lines is that HT29 cells were derived from primary colorectal cancer, which is less invasive
by nature, while SW620 cells are highly metastatic. HT29 cells require a lower concentration of the
chemotherapeutic agent 5-fluorouracil (5-FU) to decrease its viability by 50% compared to SW620 cells,
which proves the SW620 cell line has a higher resistance towards anticancer agents than the HT29 cell
line [20].
Results acquired from the MTT assay present the successful inhibition of cell proliferation in
both HT29 and SW620 cells in a dose-dependent manner. As shown in Table 1, the overall inhibitory
concentrations of DK1 and natural curcumin towards HT29 cells were lower than that of SW620 cells.
This was probably due to the SW620 cells being more aggressive in nature than the HT29 cells. For the
HT29 cells, natural curcumin required a concentration of 20.2 µM to exhibit 50% inhibition within
48 h while only 7.5 µM DK1 was needed to achieve a similar efficacy; approximately three times
less than curcumin. Conversely for SW620 cells, only 14.5 µM of DK1 was needed to reduce the cell
population by 50% while natural curcumin required more than 50 µM to achieve the same effect. These
results showed that the curcumin analog DK1 is more potent than natural curcumin in inhibiting cell
proliferation and inducing cell apoptosis. Previous studies have also indicated that natural curcumin
required a concentration of 50 µM in48 h incubation time to achieve a 50% inhibitory concentration
(IC50) inHT29 cells, whereas DK1 only needed 7.5 µM to exhibit a similar cytotoxic effect [21]. As for
SW620 cells, a 96-h incubation time was needed to obtain a 50% inhibitory concentration (10 µM)
compared to DK1 (14.5 µM), which required a slightly higher concentration but only 48 h to achieve
the same cytotoxic effect [22]. Additionally, DK1 was also observed to be cytotoxic and could inhibit
the proliferation of both cell lines, albeit a greater inhibition in HT29 cell proliferation compared to
that of SW620. The AO/PI dual-staining assay was conducted to confirm that DK1 induces cell death
via apoptosis by assessing the morphological changes between the untreated cells and the DK1-treated
cells as depicted in Figure 2.Apart from the fluorescent signal given off by the cells, distinct features of
apoptosis such as membrane blebbing, chromatin condensation, and cell shrinkage were observable.
The AO stain can readily enter viable cells through the membrane pores due to its small molecular
size and fluoresces green when observed using a fluorescent microscope; the PI stain is unable to
enter the cell structure unless the cell membrane is compromised as a result from dying or dead
cells [15]. Also, based on results from the annexin-V/FITC analysis in Figure 3, a population shift was
observable in both cell lines. The externalization of phosphatidylserine occurs due to the disintegration
of the membrane structure, indicating that DK1 induced cell death via apoptosis in both HT29 and
SW620 cells. These results are also in agreement with previous studies conducted on breast cancer
cells and osteosarcoma cells, which concluded that DK1 induces cell death through the apoptosis
pathway [15,16].
To further assess the mode of cell death, the cell cycle activity was analyzed after the cells had
been treated with the three concentrations (IC25, IC50, and IC75) of DK1. During a cell cycle there are
checkpoints that play significant roles. They help to regulate the cell cycle by temporarily arresting the
cell, thereby allowing time for cellular repair mechanisms to take place and reversing any incurred
DNA mutation, or activating programmed cell death in the case of irreversible cellular damage and
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causing DNA fragmentation that is usually accompanied by increased sub-G0/G1 population in these
apoptotic cells [17,23]. Irregular cell cycle activity then leads to enhanced cancer proliferation as the
cell is unable to activate cell death mechanisms, thus allowing cancerous cells to further proliferate.
In Figure 4, an increasing trend of the sub-G0/G1 population of HT29 cells was seen as the dose of DK1
increased. A similar trend was observed in SW620 cells where there was a significant accumulation of
cells in the sub-G0/G1 phase. However, as the accumulation at the sub-G0/G1 phase was much higher
in HT29 with a population of 74% compared to SW620 (subG0/G1 population of 23%), these results
show that DK1 is more potent in inducing apoptosis inHT29 cells than in SW620 cells. The treatment
with DK1 caused cell cycle arrest in both cell lines at the S phase, shown by the significant accumulation
in the S phase and a significant decrease in the population at the G2/M phase.
Programmed cell death via apoptosis can be activated through two main pathways: the extrinsic
pathway (activated by death receptors) and the intrinsic pathway (mitochondrial-dependent) [24,25].
When a stimulus such as a drug is administered, the mitochondrial membrane becomes permeabilized,
leading to membrane rupture [18,26]. Apoptosis is mainly regulated by the caspase cascade [18].
When a cell undergoes apoptosis via the intrinsic pathway, the mitochondrial membrane depolarizes,
becomes permeabilized, and starts to rupture, releasing pro-apoptotic factors such as cytochrome c
and Smac, which leads to the formation of apoptosomes [18,27]. This then leads to the activation of a
caspase cascade where, in this case, the activation of caspase-9 then activates effector caspases such as
caspase-3, caspase-6, and caspase-7 [18]. On the other hand, when apoptosis occurs via an extrinsic
pathway, the death receptors on the surface of the cell membranes are triggered and subsequently
activate caspase-8, which will correspondingly activate effector caspases [18]. It was shown in Figure 5
that DK1 triggers depolarization of the mitochondrial membrane potential in both HT29 and SW620
cells, signifying that apoptosis occurrence was mitochondriadependent. However, concluding the
mode of apoptosis solely based on the JC-1 assay is inadequate; therefore, several apoptotic-related
genes and proteins were quantified in order to determine the mechanism of DK1 in inducing cell death.
As shown in Figure 6, caspase-3, caspase-9, and cytochrome C genes were significantly
up-regulated when HT29 cells were treated with the IC50concentration of DK1 while in SW620 cells,
caspase-8 and caspase-9 were significantly upregulated while caspase-3 was downregulated. These
results suggest that both colon cancer cell lines underwent apoptosis via an intrinsic pathway upon
treatment with DK1.The mechanistic activity of the curcumin analog DK1 was further examined
using the human apoptosis proteome profiler. DK1 was able to upregulate the expression of
several pro-apoptotic proteins (Table 2) such as pro-caspase-3, cleaved caspase-3, Bax, cytochrome
C, HTRA2/Omi, and Smac/Diablo proteins. Bax is an extensively studied and widely known
pro-apoptotic member of the Bcl-2 protein family of apoptosis-related proteins [27]. Bax regulates the
mitochondrial membrane potential, which leads to the secretion of cytochrome C [18,24]. The secretion
of cytochrome C induces the activation of the caspase cascade, leading to apoptosis [24]. HTRA2/Omi
and Smac/Diablo proteins are also pro-apoptotic proteins that play significant roles as they help
reduce the cell’s inhibition towards apoptosis [24,28,29]. However, upregulated expression of these
pro-apoptotic proteinswere seen in the HT29 cells; in SW620 cells, only the HTRA2/Omi protein
expression was upregulated and the other proteins did not show any significant difference in
expression.This suggests that oxidative stress may partially contribute to the mitochondrial changes
causing apoptosis in the SW620 cells [30]. The overall results show that DK1 is more potent to HT29
cells than SW620 cells, suggesting that it would potentially be a more effective anticancer agent for
primary colon adenocarcinoma and more appropriate as an anticancer agent for treating colon cancer
at early stages before the cancer metastasizes.
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4. Materials and Methods
4.1. Synthesis of Curcumin Analogue, DK1
The curcumin analog DK1 used as treatment in this study was obtained from Dr. Nadeem Akhtar
of Universiti Malaysia Pahang. DK1 was synthesized as outlined by Ali et al. [15].
4.2. Cell Culture
The HT29 cell line was maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium
while the SW620 cell line was maintained in Dulbecco’s Modified Eagle Medium (DMEM).Both media
were supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin (Life Technologies,
Carlsbad, CA, USA) resulting in the complete growth media used to maintain the cell cultures.
Cells were harvested to conduct assays as confluence reached 80% using TrypLE™ Express
(Life Technologies, Carlsbad, CA, USA).Cell lines were maintained in culture flasks in 37◦C humidified
incubator provided with 5% CO2.
4.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide(MTT) Assay
The MTT assay was conducted as outlined by Mosmann with slight modifications [31]. Briefly,
each cell line was seeded in 96-well plates at a concentration of 5 × 104 cells/mL. The cells were then
incubated in a humidified CO2 incubator overnight to allow for cell attachment. The following day,
natural curcumin and DK1 was added to the wells by two-fold serial dilution. The cell viability was
measured at 24, 48, and 72 h posttreatment. The MTT reagent (Merck, Kenilworth, NJ, USA) was added
at a volume of 20 µL of 5 mg/mL in each well and incubated for four hours. Afterwards, dimethyl
sulfoxide (DMSO) was added to each well to solubilize the formazan crystals formed. The plates were
then read using an ELISA plate reader at a wavelength of 570 nm (Bio-Tek Instruments, Winooski,
VT, USA). The optical density values obtained were used to plot a dose–response curve. Triplicates
were carried out for each cell line. The following formula was used to determine the percentage of
viable cells.
Percentage of Cell Viability =
OD sample at 570 nm
OD control at 570 nm
× 100% (1)
The concentration of DK1 that reduced cell viability by 25%, 50%, and 75% compared to
the untreated cells was called the inhibitory concentration (IC25, IC50, and IC75, respectively)
and was determined by extrapolation from the dose–response curve of cell viability against
treatment concentration.
4.4. Cell Treatment
Based on the results of the MTT assay, three doses of DK1 (IC25, IC50, and IC75) were used for
the following assays. The three doses—IC25, IC50, and IC75—of DK1 were administered to HT29 and
SW620. As DK1 is water-insoluble, it was first dissolved in DMSO prior to mixing with complete
growth media for treatment of the cells where the final DMSO volume administered to cells was less
than 0.1%.
4.5. Acridine Orange/PropidiumIodide (AO/PI) Double-Staining Assay
AO/PI double staining was assayed with the aim of determining the morphological changes
inHT29 and SW620 cells upon DK1 treatments. The cells were seeded in 6-well culture plates at a
concentration of 3.0× 105 cells/well and incubated overnight. The next day, the cells were treated
with the three concentrations (IC25, IC50, and IC75 values) of DK1 for 48 h. After incubation, the cells
were detached and harvested. A 1:1 ratio of AO (10 µg/mL) toPI (10 µg/mL) was used to incubate the
cells. The incubated cells were then viewed under a fluorescence microscope (Nikon, Tokyo, Japan) at
200× magnification with a filter range of 450–490 nm.
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4.6. Cell Cycle Analysis
The cells were seeded in 6-well culture plates at a concentration of 3.0 × 105 cells/well and were
incubated overnight. Three concentrations of DK1 were treated the following day. After 24 and 48 h,
all cells were collected by trypsinization into phosphate buffer solution (PBS). The resulting pellet
was fixed in 70% ethanol and stored at −20◦C. After a week, the fixed cells were washed with PBS
and processed using the Cycletest™ PLUS DNA Reagent Kit (BD Biosciences, San Jose, CA, USA)
as outlined provided by the kit. Then, the cells were subjected to flow cytometric analysis using a
NovoCyte flow cytometer (ACEA Biosciences Inc., San Diego, CA, USA).
4.7. Annexin-V/FITC Assay
The Annexin-V/FITC assay was carried out using the Annexin-V/FITC Apoptosis Detection Kit
(BD Biosciences, San Jose, CA, USA). The cells were seeded in 6-well culture plates at a concentration
of 3.0 × 105 cells/well and were incubated overnight. The seeded cells were treated with the three
concentrations (IC25, IC50,and IC75 values) of DK1 for 48 h. After the incubation times, the treated
cells were all collected and harvested and the resulting pellets were immediately resuspended in the
provided binding buffer and subsequently stained with 5 µL FITC annexin V and 5 µL PI. The mixture
was left to incubate at room temperature for 15 min. Then, the cells were analyzed using a NovoCyte
flow cytometer (ACEA Biosciences Inc., San Diego, CA, USA).
4.8. JC-1 (Mitoscreen) Assay
The BD™ Mitoscreen Mitochondria Membrane Potential Detection (JC-1) Kit (BD Biosciences,
San Jose, CA, USA) was used to measure the depolarization of the mitochondrial membrane potential.
The cells were seeded in 6-well culture plates at a concentration of 3.0 × 105 cells/well and were
incubated overnight. The seeded cells were treated with three concentrations (IC25, IC50,and IC75)of
DK1. After 24 and 48 h, the cells were collected and harvested by trypsinization into PBS and then
centrifuged at 2000 rpm for 5 min. The cells were incubated with 500 µL of JC-1 working solution.
The JC-1 working solution contained the JC-1 stock solution and assay buffer at a ratio of 1:100.
This mixture was incubated at 37 ◦C for 15 min. Finally, the cells were washed with the assay buffer
twice before proceeding to the flow analysis using a NovoCyte flow cytometer (ACEA Biosciences Inc.,
San Diego, CA, USA).
4.9. Quantitative Real-Time PCR Assay
Total RNA was isolated from the untreated and DK1-treated (IC50) cells using the QIAGEN
RNeasy Kit (Qiagen, Hilden, NRW, Germany) according to the manufacturer’s protocol. The purity
and concentration of the isolated RNA were measured using a Nanodrop™ spectrophotometer
(Thermo Fisher Scientific Inc., San Diego, CA, USA) and the integrity of the RNA was determined by
running a standard agarose gel. Then, 1 µg of the RNA was converted to cDNA using the RevertAid
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., San Diego, CA, USA) according to the
manufacturer’s protocol. Afterwards, real-time PCR was carried out using the Maxima SYBR Green
qPCR Master Mix (Thermo Fisher Scientific Inc., San Diego, CA, USA) on the Eco™ Real-Time PCR
System (Illumina Inc., San Diego, CA, USA). The qRT-PCR regime included initiation at 95 ◦C for 10 s,
and annealing/extension at 58 ◦C for 30 s. This process was repeated for 40 cycles and the results
were analyzed using EcoStudy Software v.4.0. (San Diego, CA, USA) based on the efficiency of the
primers. The results were analyzed to two housekeeping genes: ACTB and 18S rRNA. The fold change
values were calculated by comparing the results of the untreated group and the DK1-treated group.
The accession number and sequence of the selected genes are illustrated in Table 3.
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Table 3. The accession numbers and sequences of the primers used in the quantitative real-time PCR assay.
Gene Accession No. Forward Sequence(5′3′) Reverse Sequence(5′3′) Amplicon Size
Caspase-3 NM_004346 AGAACTGGACTGTGGCATTGAG GCTTGTCGGCATACTGTTTCAG 191
Caspase-8 NM_001228 CATCCAGTCACTTTGCCAGA GCATCTGTTTCCCCATGTTT 128
Caspase-9 NM_001229 TGTCCTACTCTACTTTCCCAGGTTTT GTGAGCCCACTGCTCAAAGAT 101
Bax BC014175.2 TTCTGACGGCAACTTCAACT CAGCCCATGATGGTTCTGAT 153
Cytochrome c NM_018947.5 GGGCCAAATCTCCATGGTCT GGCAGTGGCCAATTATTACTC 246
Cyclin A M25753.1 GGTGTCACTGCCATGTTTATTG TCTGTCTGATTTGGTGCTTAGT 160
CDK 2 NG_029877.1 CCACAGCTACTCACCTGTTATC ATGTCAACCCACCTTAATCTCTC 173
ACTB NM_001101.3 AGAGCTACGAGCTGCCTGAC AGCACTGTGTTGGCGTACAG 184
18srRNA X03205 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 151
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4.10. Proteome Profiling
Total protein from HT29 and SW620 human colon cancer cell lines were extracted using 600 µL
of radio immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, 150 mMNaCl, 1.0% TritonX-100,
0.5% sodium deoxycholate and 0.1% SDS) and supplemented with 10 mg of protease inhibitor cocktail
(Roche, Basel, Switzerland). The extracted protein was then quantified using Bradford assay (Sigma,
St. Louis, MO, USA). The proteome profiling assay was conducted to confirm the induction of
cell death via apoptosis and the expressed protein levels were determined using the Proteome
Profiler™ Array Human Apoptosis Array Kit (R&D Systems, Inc., Minneapolis, MN, USA), conducted
according to the manufacturer’s protocol provided in the kit. The membrane was scanned using the
ChemiDoc XRS (BioRad, Hercules, CA, USA) and analyzed using Image Lab™ Software version 6.0.0
(Bio-Rad Laboratories, Inc., Hercules, CA, USA).
4.11. Statistical Analysis
All data presented with statistical mean ± standard deviation (SD) from three independent
experiments using GraphPad Prism ver. 7.00 (GraphPad Software, Inc., La Jolla, CA, USA) was used
to perform all statistical analysis. The statistical comparison analysis was done using the one-way
analysis of variance (ANOVA), followed by Tukey’s post hoc test. The significance was set at p < 0.05.
The comparisons done to obtain statistical significance was between the control (untreated) group and
DK1-treated groups.
5. Conclusions
Overall, the curcumin analog DK1 was found to be more potent towards the less aggressive
human colon cancer cell line, HT29, in inducing cell death via the intrinsic apoptotic pathway. This is
supported by the upregulation of pro-apoptotic genes and proteins such as caspase-3, caspase-9, Bax,
and cytochrome C. Further studies need to be conducted to assess the bioavailability potential of DK1
in vivo to confirm its efficacy as an anti-colon carcinoma drug.
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